János Tibor Kis

Dr. János Tibor Kis

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2011 in International Immunology
Verified
Journal Article
Open access
PDF file
PEPeter Engelmann
Peter Engelmann
KFKlára Farkas
Klára Farkas
JKJános Tibor Kis
János Tibor Kis
GRGeoffrey Richman
Geoffrey Richman
ZZZhaoyun Zhang
Zhaoyun Zhang
TOTihamér Orbán
Tihamér Orbán
Recently described forkhead box protein 3 (FoxP3) transcription factor is a key molecule in CD4+ CD25hi+ T-cell characterization. Invariant NK T (iNKT) cells are also characterized as regulatory cells modulating the immune response by rapidly producing Th1 and Th2 cytokines. We aimed to analyze cellular markers important in regulatory features of human iNKT cells and to study their role in functional assays. iNKT cells were single cell sorted from peripheral mononuclear cells of healthy individuals after immunostaining of invariant TCR α-chain. We found FoxP3 expression in human iNKT clones. Randomly selected iNKT cell clones (CD4+, double negative, CD8+) expressed FoxP3 mRNA and protein at different levels upon stimulation as supported by various approaches. FoxP3 mRNA and protein expression was detected in unstimulated iNKT cells as well. Furthermore, different stimulations changed the FoxP3 expression in iNKT cells over time and the most dramatic changes were observed upon anti-CD3 stimulation. Both the supernatant of iNKT cells and iNKT cells themselves exerted similar stimulation effects on PBMC proliferation in functional assays and these stimulations showed a negative correlation with FoxP3 expression. Our data indicate that the FoxP3 expression in iNKT cells may be a key transcriptional factor in controlling the regulatory function of the iNKT cells.

6 August 2021 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
JKJános Tibor Kis
János Tibor Kis
GNGábor Nagy
Gábor Nagy
GKGábor Kovacs
Gábor Kovacs
Introduction The latest Position Statement of the American Diabetes Association/European Association for the Study of Diabetes proposes the use of a fixed-ratio combination (FRC) of a long-acting basal insulin and a glucagon-like peptide-1 receptor agonist as part of treatment intensification. This study aimed to assess the effectiveness of the insulin glargine + lixisenatide (iGlarLixi) FRC on glycaemic control and hypoglycaemia in real-life settings. Methods This non-interventional, 26-week study included participants aged 18–80 years with suboptimally controlled type 2 diabetes (T2D) using oral antidiabetics (OADs) ± basal insulin therapy. The primary efficacy endpoint was the proportion of participants who achieved at least a 1% decrease in glycated haemoblobin (HbA1c) level from baseline to week 26. Results Of the 441 participants eligible for entry into the study, 353 were included in the efficacy analyses. These individuals were switched from OADs without (282 [79.9%]) or with (71 [20.1%]) insulin-based treatment. A reduction in HbA1c of at least 1.0% (primary endpoint) was achieved by 215 subjects (60.9%). All glycaemic variables (mean ± standard deviation) improved significantly during follow-up (HbA1c, from 8.9 ± 1.31 to 7.4 ± 0.97%; fasting blood glucose, from 9.0 ± 2.18 to 6.9 ± 1.23 mmol/L; postprandial blood glucose, from 11.3 ± 2.33 to 8.5 ± 1.46 mmol/L; p < 0.001 for all). Body weight also decreased during follow-up, from 90.5 ± 18.03 to 88.2 ± 17.75 kg (p < 0.001). Overall, 41 participants (9.3% of the safety population) self-reported 101 non-severe hypoglycaemic episodes (incidence rate 0.498 events/person-year). There were no severe hypoglycaemic episodes reported. Gastrointestinal adverse events were reported by five participants (1.1% of the safety population). The vast majority (96.6%) of the study population continued iGlarLixi treatment after the final visit. Conclusion The results of this non-interventional study confirmed the efficacy results of the randomized controlled trial programme of the iGlarLixi FRC in a real-life setting. iGlarLixi significantly improved glycaemic control in association with a low frequency of hypoglycaemia and gastrointestinal adverse events in a heterogeneous population of participants with T2D suboptimally controlled with OADs ± basal insulin.

17 June 2024 in COVID
Verified
Journal Article
Open access
PDF file
LSLászló Schandl
László Schandl
BKBarnabás Kiss
Barnabás Kiss
ZLZoltán Lengyel
Zoltán Lengyel
JKJános Tibor Kis
János Tibor Kis
GWGábor Winkler
Gábor Winkler
The COVID-19 pandemic has placed enormous pressure on healthcare systems. In the first line of the “war” against the virus, hospitals tried to maintain their general operations, while supplementing their services with COVID-19 patient care. To tackle the new difficulties, hospitals had to develop strategic response plans, and were in need of finding the most effective management structure for their institution. The focus of this paper is the aforementioned management structures. After overviewing the international literature, we identified three different approaches and we named them the Horizontal, Vertical, and Intermedier Approach. The separation is based on the following features: decision making, information distribution, command forwarding, intra-hospital communication channels, hierarchy, and control. After summarizing the international experiences, we introduce a Hungarian centrum hospital’s approach, as the institution was assigned to fulfil COVID-19 centrum hospital duties in the middle of the first wave. The North-Buda Szent János Central hospital was in need of restructuring their management structure, and the leadership decided to transform it into a hierarchical, vertical structure, operating with centralized decision making and personal control. This control–command system idea came from the hospital’s Internist Head Coordinator Physician, who is the first author of our article, and had serious military medicine experiences (in Afghanistan).

1 April 2023 in Diabetologie und Stoffwechsel
Verified
Journal Article
Closed access
MHMartin Haluzík
Martin Haluzík
JSJochen Seufert
Jochen Seufert
CGCristian Guja
Cristian Guja
MBMireille Bonnemaire
Mireille Bonnemaire
GBGrégory Bigot
Grégory Bigot
NFNick Freemantle
Nick Freemantle
Fragestellung Die Wirksamkeit und Sicherheit von iGlarLixi vor dem Frühstück verabreicht wurde in verschiedenen randomisierten kontrollierten Studien nachgewiesen. Ob der Zeitpunkt der Verabreichung die Wirksamkeit in der Versorgungsrealität der klinischen Praxis beeinflussen könnte, ist nicht bekannt. Methodik In der europäischen REALI-Pooldatenbank analysierten wir Daten auf Patientenebene von 1.303 Menschen mit Typ-2-Diabetes, die 24 Wochen lang mit iGlarLixi behandelt wurden. Davon erhielten 33% die Injektion vor dem Frühstück, 20% vor dem Mittagessen, 31% vor dem Abendessen, während 16% den Zeitpunkt der Injektion wechselten. Ergebnisse Insgesamt waren die Ausgangs-Charakteristika der Gruppen ähnlich, mit einem Alter [Mittelwert±Standardabweichung] von 61±9,0 Jahren, einem BMI von 32,2±5,5 kg/m2 und einer medianen Diabetesdauer von 9 Jahren. Die Typ-2-Diabetespatienten hatten zuvor 1 (57%) oder ≥ 2 (43%) orale Antidiabetika eingenommen. Insgesamt 590 Personen (45%) wurden im Median 2,5 Jahre lang mit Insulin vorbehandelt. Der HbA1c-Wert verbesserte sich von 9,1±1,4% zu Studienbeginn auf 7,7±1,2% zu Woche 24, mit einem mittleren Rückgang nach der Methode der kleinsten Quadrate [95%-KI] von –1,4 [–1,50; –1,36]% und der deutlichsten Verringerung in der Vor-dem-Frühstück-Gruppe (–1,57 [–1,68; –1,45]%). Der Nüchternplasmaglukose-Wert sank bis Woche 24 um 50,0±54,2 mg/dl und das Körpergewicht um 1,8±6,6 kg, ohne Unterschied zwischen den Gruppen. Schlussfolgerungen Diese Analyse bestätigt die Wirksamkeit von iGlarLixi zu allen Verabreichungs-Zeitpunkten; die Gabe vor dem Frühstück könnte bevorzugt werden, wenn eine Wahl möglich ist. Encore-Einreichung. Unterstützt durch Sanofi. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

29 September 2023 in IME - Az egészségügyi vezetők szaklapja
Verified
Journal Article
Open access
PDF file
GKGábor Kovács
Gábor Kovács
EMElemér Mohos
Elemér Mohos
JKJános Tibor Kis
János Tibor Kis
ATAdam Tabak
Adam Tabak
PGPéter Gerendy
Péter Gerendy
ZKZoltán Kaló
Zoltán Kaló
Annak ellenére, hogy a 2-es típusú cukorbetegségben szenvedő elhízott betegek kezelése népegészségügyi prioritás, és a bariátriai műtétek jelentős egészségnyereséget és egészségügyi költségmegtakarítását eredményeznek e betegeknél, ezek a műtétek csak a magán egészségügyi szektorban elérhetőek egy szűk vagyonos réteg számára. Számos akadály gátolja az elhízott cukorbetegeknél végzett bariátriai műtétek széles körű elterjedését, így az egészségpolitikai döntéshozók támogatásának hiánya, a bariátriai műtétek szerepének meghatározatlansága az egészségügyi rendszerben, ebből következően az ilyen műtétek közfinanszírozásának hiánya, közfinanszírozott kapacitások korlátozottsága, valamint a szakmai kompetenciák kidolgozatlansága. A szerzők ezen korlátok áthidalására tesznek konszenzusos javaslatot.